This Obesity Drug Stock Surges 60% on Phase 3 News
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Regularly reviewing your retirement plan is essential for long-term success. Find out when to make those important assessments.
20,077 articlesA notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
A tech-era billionaire announces an eight-figure cap on his children's inheritance, promising the remainder to charit...
Robinhood shares jumped on regulatory news and improving sentiment for retail platforms, even as crypto markets faced...
As Anthropic prepares an IPO, history warns that sky-high private valuations rarely translate into smooth public-mark...
Iren is pursuing a bold AI infrastructure push with a $4.4 billion target. This article breaks down what that means f...
As AI accelerates, energy and data infrastructure firms are in the spotlight. Here are two stock ideas that could rid...
Three practical lessons from SpaceX’s IPO can guide investors as Anthropic and OpenAI approach the market. Learn how ...
When one tech giant climbs and another stumbles, the market often stays coldsweat steady. Learn how Micron’s strength...
If you had $1,000 to put into a single stock this July, MercadoLibre could stand out for growth potential and a robus...
A senior executive walked away from a high-profile role with no plan and, within a day, laid the groundwork for a lea...
Insider moves can signal a lot about a company’s near-term plans and risk. This deep dive looks at Adaptive Biotechno...